Skip to main content
MerckIn development

Merck & Co. stock advances as COPD trial opens new catalyst path

Source: Autobound Signal API · 95 signals tracked for Merck · updated

Get Merck's live signals in Claude or ChatGPT, or by API

AskWhat changed at Merck this week? Use Autobound signals for merck.com.

What happened

Merck & Co. has initiated ENHANCE-3, a Phase 3 clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of COPD exacerbations.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Merck & Co. has started a new late-stage study for OHTUVAYRE as the drugmaker seeks to expand the clinical evidence around its COPD treatment. In a November 3 statement, Merck announced the initiation of ENHANCE-3, a Phase 3 randomized trial evaluating OHTUVAYRE, also known as ensifentrine, for the prevention of COPD exacerbations. Recruitment has begun, with the first participants enrolling in the United States. Merck said the study is designed for adults with COPD who have a history of moderate or severe exacerbations while receiving standard care. The company is positioning the trial as a step toward strengthening the evidence base for a medicine already approved in the United States for maintenance treatment of COPD. ENHANCE-3 is planned as a randomized, double-blind, placebo-controlled study involving approximately 2,136 patients in 28 countries. Participants will receive either OHTUVAYRE twice daily or placebo, with both groups continuing standard-of-care treatment. The primary endpoint is the annualized rate of adjudicated moderate or severe COPD exacerbations over 52 weeks. Secondary measures include lung function, health-related quality of life, severe exacerbations and overall safety. The design focuses on adults aged 40 to 80 with a confirmed COPD diagnosis, stable background therapy and at least one qualifying exacerbation during the previous year. OHTUVAYRE is a...

Keep reading with a free account

The rest of this article, and every signal for Merck, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
OHTUVAYRE
Takes effect
Nov 3, 2026
Location
United States

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Nov 5, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Merck and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e5197a4a-cc28-6411-4bc9-f06358a9d7ee returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.

{
  "signal_id": "e5197a4a-cc28-6411-4bc9-f06358a9d7ee",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-05T12:26:58+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/merck-co-stock-advances-as-copd-trial-opens-new-catalyst-path/70463526",
    "title": "Merck & Co. stock advances as COPD trial opens new catalyst path - ad-hoc-news.de",
    "excerpt": "Merck & Co. has started a new late-stage study for OHTUVAYRE as the drugmaker seeks to expand the clinical evidence around its COPD treatment. In a November 3 statement, Merck announced the initiation of ENHANCE-3, a Phase 3 randomized trial evaluating OHTUVAYRE, also known as ensifentrine, for the prevention of COPD exacerbations. Recruitment has begun, with the first participants enrolling in the United States. Merck said the study is designed for adults with COPD who have a history of moderate or severe exacerbations while receiving standard care. The company is positioning the trial as a step toward strengthening the evidence base for a medicine already approved in the United States for maintenance treatment of COPD. ENHANCE-3 is planned as a randomized, double-blind, placebo-controlled study involving approximately 2,136 patients in 28 countries. Participants will receive either OHTUVAYRE twice daily or placebo, with both groups continuing standard-of-care treatment. The primary endpoint is the annualized rate of adjudicated moderate or severe COPD exacerbations over 52 weeks. Secondary measures include lung function, health-related quality of life, severe exacerbations and overall safety. The design focuses on adults aged 40 to 80 with a confirmed COPD diagnosis, stable background therapy and at least one qualifying exacerbation during the previous year. OHTUVAYRE is a...",
    "product": "OHTUVAYRE",
    "summary": "Merck & Co. has initiated ENHANCE-3, a Phase 3 clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of COPD exacerbations.",
    "location": "United States",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2671685_1920_1080.webp",
    "confidence": 0.95,
    "product_data": {
      "name": "OHTUVAYRE",
      "full_text": "OHTUVAYRE, also known as ensifentrine",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-05T12:26:58Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-03",
    "article_sentence": "In a November 3 statement, Merck announced the initiation of ENHANCE-3, a Phase 3 randomized trial evaluating OHTUVAYRE, also known as ensifentrine, for the prevention of COPD exacerbations."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.